Bulk Pharmaceutical API Sources for regadenoson

Bulk Pharmaceutical API Sources for regadenoson

Vendor	Vendor Homepage	Vendor Sku	API Url
Amadis Chemical		208181
Glentham Life Sciences Ltd.		GP4974
TargetMol		T2671
AbaChemScene		CS-5612
MedChemexpress MCE		HY-A0168
AKos Consulting & Solutions		AKOS026750593

Regadenoson API Sourcing Landscape

Last updated: February 19, 2026

The global supply chain for Regadenoson Active Pharmaceutical Ingredient (API) is characterized by a limited number of key manufacturers, primarily concentrated in Asia. Sourcing considerations center on quality, regulatory compliance, and cost. Lead times for bulk API procurement can range from 12 to 24 weeks, depending on supplier capacity and order volume.

What are the primary geographical sources for Regadenoson API?

The primary geographical sources for Regadenoson API are China and India. These regions dominate API manufacturing due to established chemical synthesis infrastructure, cost efficiencies, and a large pool of skilled labor.

China

Chinese manufacturers represent a significant portion of the global Regadenoson API supply. These companies often possess large-scale production capabilities and adhere to international Good Manufacturing Practices (GMP) standards. Key advantages include competitive pricing and a well-developed logistical network. However, regulatory oversight and consistency in quality assurance can vary between individual manufacturers.

• Key Attributes of Chinese API Sources:
  • High production volumes
  • Cost-competitiveness
  • Established export infrastructure
  • Variable adherence to stringent quality control

India

India is another major hub for pharmaceutical API production, including Regadenoson. Indian manufacturers are known for their strong focus on regulatory compliance, with many facilities holding certifications from major regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The presence of a robust pharmaceutical research and development ecosystem contributes to a competitive API market.

• Key Attributes of Indian API Sources:
  • Strong regulatory compliance history
  • FDA and EMA approved facilities
  • Significant R&D capabilities
  • Diverse range of manufacturers

Other Regions

While China and India are the dominant suppliers, a limited number of API manufacturers in other regions, such as Europe and North America, may also produce Regadenoson API. These sources typically cater to niche markets or supply specialized requirements, often at a higher price point due to higher labor and operational costs. Their strength lies in stringent quality control and advanced synthesis technologies.

• Key Attributes of Other Regional API Sources:
  • Premium pricing
  • Advanced synthesis technologies
  • Strict quality assurance protocols
  • Limited production capacity

What are the key quality and regulatory considerations for Regadenoson API sourcing?

Sourcing Regadenoson API necessitates rigorous adherence to quality and regulatory standards to ensure the safety and efficacy of the final drug product. Key considerations include GMP compliance, impurity profiling, and Drug Master File (DMF) availability.

Good Manufacturing Practices (GMP) Compliance

All Regadenoson API sourced must be manufactured in facilities that comply with current Good Manufacturing Practices (cGMP). Compliance ensures that the API is consistently produced and controlled according to quality standards appropriate for its intended use. Regulatory bodies like the FDA and EMA conduct inspections to verify adherence.

• Essential GMP Documentation:
  • Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP)
  • FDA establishment registration
  • Audits and site visit reports

Impurity Profiling and Control

Thorough impurity profiling is critical for Regadenoson API. Manufacturers must identify, quantify, and control all potential impurities, including process-related impurities, degradation products, and residual solvents. These impurities can impact the safety and efficacy of the final drug product. Specifications for impurities should align with ICH guidelines.

• Critical Impurity Parameters:
  • Related substances (specified and unspecified)
  • Residual solvents
  • Heavy metals
  • Enantiomeric purity

Drug Master Files (DMFs)

The availability of a comprehensive Drug Master File (DMF) is a significant advantage when sourcing Regadenoson API. A DMF contains detailed information about the manufacturing process, facilities, and controls for the API, which can be referenced by drug product manufacturers in their regulatory submissions.

• Types of DMFs:
  • Type II DMF (United States)
  • Active Substance Master File (ASMF, Europe)

Analytical Method Validation

All analytical methods used for testing Regadenoson API, including those for identity, purity, and potency, must be fully validated. Validation ensures that the methods are accurate, precise, specific, and robust for their intended purpose, meeting pharmacopoeial standards (e.g., USP, EP).

• Validation Parameters:
  • Accuracy
  • Precision
  • Specificity
  • Linearity
  • Range
  • Limit of Detection (LOD)
  • Limit of Quantitation (LOQ)
  • Robustness

What are the typical lead times and pricing structures for bulk Regadenoson API?

Lead times and pricing for bulk Regadenoson API are influenced by manufacturing capacity, order volume, and current market demand. Establishing reliable supply chains involves understanding these factors to manage inventory and control costs effectively.

Lead Times

The typical lead time for bulk Regadenoson API can range from 12 to 24 weeks. This period encompasses manufacturing, quality control testing, batch release, and shipping. Smaller, non-contractual orders may experience longer lead times, while large, contracted orders might benefit from prioritized production schedules.

• Factors Affecting Lead Times:
  • Supplier production schedules
  • Raw material availability
  • Quality control testing duration
  • Shipping logistics and customs clearance

Pricing Structures

Pricing for Regadenoson API is generally quoted on a per-kilogram basis. The price is subject to significant volume discounts. For example, prices might range from $800 to $1,500 per kilogram for smaller quantities (e.g., 1-10 kg), potentially dropping to $400 to $800 per kilogram for bulk orders (e.g., 100 kg or more). These are indicative ranges and can fluctuate based on market dynamics.

• Price Influencers:
  • Order volume
  • Purity specifications
  • Regulatory support (e.g., DMF filing)
  • Contractual agreements
  • Global API market conditions

Contract Manufacturing and Supply Agreements

For consistent and reliable supply, pharmaceutical companies often enter into long-term contract manufacturing agreements (CMAs) or supply agreements with API manufacturers. These agreements typically specify production volumes, quality standards, pricing, delivery schedules, and intellectual property protection.

• Key Elements of Supply Agreements:
  • Guaranteed supply volumes
  • Fixed or capped pricing
  • Defined quality specifications
  • Intellectual property clauses
  • Force majeure provisions

What are the common challenges in sourcing Regadenoson API?

Sourcing Regadenoson API presents several challenges that require proactive management by procurement and R&D professionals. These include supply chain disruptions, quality control inconsistencies, and intellectual property concerns.

Supply Chain Disruptions

Global supply chains are susceptible to disruptions from geopolitical events, natural disasters, and public health crises (e.g., pandemics). These events can impact raw material availability, manufacturing output, and transportation, leading to API shortages or significant price increases. Diversifying suppliers across different geographical regions can mitigate this risk.

• Potential Disruption Sources:
  • Trade disputes and tariffs
  • Transportation network failures
  • Factory shutdowns due to environmental regulations
  • Raw material scarcity

Quality Control Inconsistencies

Ensuring consistent quality across different batches and suppliers can be challenging. Variations in manufacturing processes, analytical testing protocols, and quality management systems among suppliers can lead to batch-to-batch variability. Rigorous supplier qualification and ongoing quality audits are essential.

• Mitigation Strategies:
  • Supplier audits (pre-qualification and periodic)
  • Batch testing at an independent laboratory
  • Clearly defined quality agreements

Intellectual Property (IP) and Patent Landscape

The patent landscape surrounding Regadenoson and its manufacturing processes can affect sourcing options. Understanding existing patents, including process patents and composition of matter patents, is crucial to avoid infringement. Manufacturers must ensure they are not violating any intellectual property rights, especially when developing or using novel synthesis routes.

• IP Considerations:
  • Freedom-to-operate analyses
  • Patent expiry dates
  • Licensing agreements

Regulatory Hurdles

Navigating the complex regulatory requirements of different countries can be a significant challenge. Ensuring that the API manufacturer's facility and processes meet the standards of the target markets (e.g., FDA, EMA, PMDA) requires detailed documentation and compliance. Changes in regulatory landscapes can also impact supply.

• Regulatory Compliance Focus:
  • DMF submissions and updates
  • Site inspections by regulatory authorities
  • Compliance with pharmacopoeial standards

What are the future trends in Regadenoson API sourcing?

The future of Regadenoson API sourcing is likely to be shaped by advancements in manufacturing technologies, increased emphasis on supply chain resilience, and evolving regulatory expectations.

Advanced Manufacturing Technologies

The adoption of advanced manufacturing technologies, such as continuous manufacturing and flow chemistry, could lead to more efficient, sustainable, and cost-effective production of Regadenoson API. These technologies offer better process control, reduced waste, and smaller facility footprints.

• Potential Technology Impacts:
  • Improved process yields
  • Reduced environmental impact
  • Enhanced batch consistency
  • Faster production cycles

Supply Chain Resilience and Diversification

Following recent global disruptions, there is an increasing focus on building more resilient and diversified supply chains. This may involve near-shoring or reshoring API manufacturing capabilities, dual-sourcing strategies, and greater transparency across the supply network.

• Resilience Strategies:
  • Geographic diversification of suppliers
  • Strategic raw material stockpiling
  • Enhanced supply chain visibility platforms

Increased Focus on Sustainability

Environmental, social, and governance (ESG) factors are becoming more prominent in API sourcing decisions. Manufacturers demonstrating strong sustainability practices, including reduced energy consumption, waste minimization, and responsible chemical sourcing, will be increasingly preferred.

• Sustainability Drivers:
  • Green chemistry principles
  • Reduced carbon footprint
  • Ethical labor practices
  • Water conservation

Digitalization and Data Analytics

The integration of digitalization and advanced data analytics in API manufacturing and supply chain management will improve efficiency and decision-making. This includes using AI for process optimization, blockchain for supply chain traceability, and predictive analytics for demand forecasting.

• Digitalization Applications:
  • Real-time process monitoring
  • Predictive maintenance of equipment
  • Automated quality control
  • Enhanced inventory management

---

Key Takeaways

• Geographic Concentration: Regadenoson API manufacturing is predominantly located in China and India, driven by cost and infrastructure advantages.
• Quality & Regulatory Imperative: Stringent adherence to GMP, thorough impurity profiling, and comprehensive DMFs are critical for API sourcing.
• Lead Times & Cost: Expect lead times of 12-24 weeks and pricing ranging from $400-$1,500/kg depending on volume and supplier.
• Sourcing Challenges: Supply chain disruptions, quality variations, and IP considerations require robust risk mitigation strategies.
• Future Outlook: Advanced manufacturing, supply chain resilience, sustainability, and digitalization are shaping the future of API sourcing.

---

Frequently Asked Questions

What is the typical purity required for Regadenoson API for pharmaceutical use?

The typical purity requirement for Regadenoson API is ≥99.0%, as per pharmacopoeial standards (e.g., USP, EP). Specific limits for individual impurities are also defined and must be met.

How can I verify the GMP compliance of a Regadenoson API supplier?

Verification of GMP compliance can be achieved through reviewing the supplier's regulatory filings (e.g., FDA establishment registration, CEP), requesting recent audit reports, conducting an on-site audit of their manufacturing facilities, and ensuring they have a robust quality management system in place.

What is the impact of patent expiry on Regadenoson API sourcing?

The expiry of key patents related to Regadenoson can open opportunities for generic API manufacturers to enter the market, potentially increasing competition, driving down prices, and expanding sourcing options. However, it is crucial to also consider process patents which may still be in effect.

Are there any specific regional regulatory requirements for Regadenoson API that differ significantly?

Yes, regulatory requirements differ. For example, the U.S. FDA requires Type II DMFs, while Europe uses the ASMF system. Each regulatory body has specific guidelines on impurity limits, analytical method validation, and stability testing that must be addressed.

What are the storage conditions recommended for bulk Regadenoson API to maintain its stability?

Regadenoson API is typically stored under controlled room temperature conditions (e.g., 20-25°C), protected from light and moisture. Specific storage recommendations should be obtained from the manufacturer's Certificate of Analysis (CoA) and Safety Data Sheet (SDS), as stability can vary based on the specific polymorphic form and excipients if any.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA Website Address] (Note: Actual URL would be inserted here if available for a specific guidance document.) [2] European Medicines Agency. (n.d.). Active Substance Master Files (ASMF). Retrieved from [EMA Website Address] (Note: Actual URL would be inserted here if available for a specific guidance document.) [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH Website Address] (Note: Actual URL would be inserted here for relevant ICH Q guidelines.) [4] United States Pharmacopeia. (n.d.). USP General Chapters. Retrieved from [USP Website Address] (Note: Actual URL would be inserted here for relevant USP general chapters.) [5] European Pharmacopoeia. (n.d.). Ph. Eur. General Chapters. Retrieved from [EDQM Website Address] (Note: Actual URL would be inserted here for relevant Ph. Eur. general chapters.)